- by sedlv
- February 17 2023
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders-Seventure etc
(February 17, 2023) | By Maat Pharma SA.
MaaT Pharma Completes a Capital Increase of approximately €12.7 Million with the Support of Current Shareholders
Lyon, France, February 17, 2023, 7:30 am CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announced the successful completion of a capital increase of approximately €12.7 million supported by its existing shareholders including Seventure Partners, PSIM Fund represented by Bpifrance Investissement, Biocodex, Invus, Céleste Management, Skyviews Life Sciences, and Tocqueville. The funds will support the Company’s biomanufacturing expansion and ongoing and future clinical trials.